Showing results (521-530 of 622) with videos related to
Sort By:
Pageof 63
The Lancet. Oncology|October 30, 2025
Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of non-small-cell lung cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trialThorsten Fuereder, Javier Garde-Noguera, Juan José García-Mosquera, et al.Neuro-Oncology|May 31, 2022
Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trialJosé Manuel Pérez-García, Marta Vaz Batista, Patricia Cortez, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 21, 2018
Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant TrialAditya Bardia, Marina Parton, Sherko Kümmel, et al.Forensic Sciences Research|February 23, 2023
An inter-laboratory study of DNA-based identity, parentage and species testing in animal forensic geneticsSreetharan Kanthaswamy, Torsten Brendel, Luis Cancela, et al.American Journal of Clinical Oncology|October 11, 2008
Prognostic significance and diagnostic value of protein S-100 and tyrosinase in patients with malignant melanomaRaquel Andrés, Jose I Mayordomo, Carmen Visus, et al.Cancer|February 1, 2024
Comparison of outcomes for Hispanic and non-Hispanic patients with advanced renal cell carcinoma in the International Metastatic Renal Cell Carcinoma DatabaseKripa Guram, Jiaming Huang, Christian Mouchati, et al.Med (New York, N.Y.)|September 12, 2024
The DEBBRAH trial: Trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer patients with leptomeningeal carcinomatosisMarta Vaz Batista, José Manuel Pérez-García, Laia Garrigós, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 8, 2022
Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant CapecitabineKarama Asleh, Ana Lluch, Angela Goytain, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2025
Second-Line Endocrine Therapy With or Without Palbociclib Rechallenge in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: PALMIRA TrialAntonio Llombart-Cussac, Catherine Harper-Wynne, Antonia Perelló, et al.Breast (Edinburgh, Scotland)|June 16, 2024
Impact of coadministration of proton-pump inhibitors and palbociclib in hormone receptor-positive/HER2-negative advanced breast cancerSerena Di Cosimo, José Manuel Pérez-García, Meritxell Bellet, et al.Pageof 63